FDA Approved New Colon Cancer Treatment
Adult and pediatric patients with stage III colon cancer now have a new chemotherapy combination option.
Updated on Oct. 9, 2026 in Cancer
The FDA has approved the use of atezolizumab in combination with chemotherapy for patients with stage III mismatch repair-deficient colon cancer. This treatment option is now authorized for both adult and pediatric patients aged 2 years and older.
Why it matters
This approval provides a new therapeutic pathway that has demonstrated improved disease-free survival compared to standard chemotherapy alone. The update expands the available arsenal for managing this specific subset of colon cancer.
Data from the phase 3 ATOMIC/ML39057 trial showed a hazard ratio of 0.50 and a P-value of 0.0001 for disease-free survival compared to mFOLFOX6 alone. These results, which ground the approval, highlight significant improvement in the treatment group.
The players
FDA
The federal agency responsible for regulating food, tobacco, and medical products in the United States.
The details
Atezolizumab is an immunotherapy that helps the immune system identify and target cancer cells more effectively. When paired with chemotherapy agents fluoropyrimidine and oxaliplatin, it aims to prevent recurrence in patients with mismatch repair-deficient tumors. Additionally, the FDA approved a subcutaneous version of the drug combined with hyaluronidase-tqjs for eligible patients 12 years and older who weigh at least 40 kg.
Timeline
The FDA approved this colon cancer treatment on October 8, 2026.
Health Landscape
This approval follows the established framework of the ATOMIC/ML39057 clinical trial. It represents an evolution in standard care by integrating immunotherapy into established chemotherapy regimens for mismatch repair-deficient colon cancer.
Patients diagnosed with stage III mismatch repair-deficient colon cancer should discuss whether this new combination therapy is appropriate for their specific care plan. These treatment decisions are highly individual and rely on clinical assessment by an oncology team.
The takeaway
New immunotherapy options are changing how we approach stage III colon cancer treatment. If you or a family member are navigating this diagnosis, consult your oncologist about the current clinical guidelines and whether this regimen fits your health profile.
Further reading
For more on evolving oncology standards, visit our Cancer section.
More information
Review the full findings on the FDA drug approval resource page.
